News: Umeå, 2 February, 2022. Lipum (publ) recruits Dr. Fredrik Seijsing to strengthen the preclinical development of SOL-116.
Lipum's development work is in an intensive phase and an initial clinical phase 1 study is being prepared. Preclinical studies have previously shown promising results for treatment of rheumatism, but the candidate drug SOL-116 is also expected to have potential to treat other chronic inflammatory diseases.
Dr. Seijsing has a PhD in Molecular Bioscience from Wenner-Gren's institute at Stockholm University and a master's degree in Medicinal biotechnology from Umeå University. He also has industry experience as process engineer from Cobra Biologics.
"Lipum's work ahead the first clinical study is continuing as planned and, in line with our strategy, we are now strengthening our team to identify additional indications for SOL-116 in parallel with the clinical program" says CEO Einar Pontén.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: firstname.lastname@example.org, phone: +46 8 503 000 50.